Mhra Legal Presence Requirements

GAfREC, MHCTR and GBR-9 also indicate that the Commission must issue its opinion within 60 calendar days of receipt of a valid application. If a Commission requires additional information before confirming its opinion, it may issue a preliminary opinion and submit one (1) written request for additional information, clarifications or amendments to the documentation. The time required for the European Commission to receive a complete response to its request is not taken into account within the 60-day period. Some studies, including gene therapy studies, last 90 days or 180 days if an expert panel or committee is consulted. For more exceptions, see GAfREC and MHCTR. (For detailed requirements for the submission process, see Clinical Trial Lifecycle, Sub-theme Submission Process and Review Schedule.) According to the UK-GDPR and the UK-DPAct, consent to participate in research is not the same as consent as a legal basis for processing under data protection laws. For more information on the sponsor`s and investigator`s responsibilities for complying with data protection requirements (e.g. legal basis for storage and use of personal data, transparency, safeguards and data rights), see the Sponsorship section. In order to ensure compliance with these post-Brexit requirements, manufacturers and distributors of medical devices must ensure that the UKCA mark is affixed to all devices affixed to it by 1 July 2023. July 2023 in the UK, and ensure that the name and address of the UKRP appear on the label.

In addition, manufacturers and distributors must ensure that a UKRP is designated and that all medical devices are properly registered with the UK MHRA. Barclay Damon`s team of health and social services providers has experience assisting medical device manufacturers with compliance obligations and conducting due diligence related to healthcare transactions with medical device manufacturers, including those with an international presence. (For detailed information on submission requirements, see Clinical Trial Lifecycle, Submission Process and Submission Content.) Additional requirements for foreign sponsors are listed in section 5.2 of RGU-113. The MDCN and RGS-113 stipulate that contact information for the sponsor and investigator(s) must be provided to the research participant and/or his/her legal representative or guardian(s) in order to respond to trial-related requests. These guidelines relate to clinical trials of medicinal products. If your request concerns a clinical trial of a medical device, please contact For complete protocol requirements, see GBR-113. You must continue to indicate the registration number(s), if available, in section A.5. of the application form in the Integrated Search Request System (ARIS) when you prepare your application.

If this is not available at the time of application, you must email it to the MHRA at with the subject “Registration of clinical trials” within six weeks of recruitment of the first research participant. You must also provide your Research Ethics Board (REB) registration number as soon as possible. In the case of obtaining material from an adult donor who is unable to consent and which is neither a consent decision nor a non-consent is in force, UK-HTA, MCA2005, GBR-9 and GBR-37 indicate that EC authorisation is required. In addition, organs, tissues or cells of a living person may be stored and used without consent if the investigator cannot identify the person and if they are used for an EC-approved research project. Please see UK-HTA and Code-A for detailed consent requirements. In addition, according to NIHDataSftyMntrng and USA-72, all clinical trials funded by the National Institutes of Health (NIH) require a data and safety monitoring plan, and monitoring must be commensurate with risk. DSMBs are specifically required for NIH-funded multicenter clinical trials with interventions that involve potential risk to participants. For detailed information on HHS/NIH requirements, see NIHDataSftyMntrng and USA-72.

The transition period has not been extended by five minutes until midnight on June 30, 2020. In theory, the UK and EU can negotiate a deal, meaning the MHRA`s previously published requirements for a no-deal Brexit may not be necessary at the end of the transition period – 31 December 2020. This “no-deal” policy was withdrawn by the government in early 2020. The outcome of the ongoing negotiations is uncertain, but in the absence of an agreement, legal presence requirements must be taken into account. Each COE has its own application form and maintenance requirements, which can vary greatly in terms of the number of copies provided and application format requirements. However, the requirements listed below are compliant with 21CFR56 as well as US-ICH BPCS and are fundamentally consistent across all US EC. As described in GTR-4, if a minor is deemed capable of accepting decisions regarding participation in research, the researcher(s) must obtain this consent in addition to the consent of his/her legal representative and/or guardian(s). If the child does not agree, this must be respected.

Please note that ITCIL Combined Review Applications must be started and submitted using the new part of the Integrated Research Request System (IRAS) and not in the standard part of IRAS. While the regulatory requirements and fees remain the same, the application, processing and assessment steps described below pertain to non-combined requests for review. For requests for combined review, please visit the Health Research Authority website. In addition, as stated in the G-CTApp, some early human (phase I) studies with specific risk factors may require the MHRA CTU to seek the advice of an expert advisory group/commission for medicinal products for human use prior to approval. See the G-CTApp for examples where studies require expert advice and detailed requirements. In accordance with the G-Import IMPs, the sponsor of a clinical trial in the United Kingdom using IPDs imported from countries on the G-CTApprovedCountries list must require the holder of the AMI(PMI) to establish a guarantee system to verify that these IMPs have been certified by a qualified person in a listed country before being released for review.

This entry was posted on 17th November 2022. Bookmark the permalink.